Eric Dobmeier, Chinook Therapeutics CEO
Novartis adds $3.2B cash deal to M&A tally, snapping up Chinook and its late-stage kidney drugs
Novartis is putting down $3.2 billion in cash to acquire kidney-focused biotech Chinook Therapeutics and its two late-stage drugs for a …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
